Samsung Bioepis Scoops First EU Lucentis Biosimilar As 2022 Date Looms
Byooviz Biosimilar Backed By EMA Committee In June
Samsung Bioepis has seen a positive opinion in the EU for its Byooviz (ranibizumab) biosimilar treatment for wet age-related macular degeneration turned into final approval by the European Commission. The company is also leading the pack in the US.
You may also be interested in...
Biogen has launched the Samsung Bioepis-developed Byooviz version of Lucentis in Canada, marking the first and only ranibizumab biosimilar to be approved and introduced in the market.
Stada and Xbrane have celebrated the approval by the UK’s MHRA of the pair’s Ximluci ranibizumab biosimilar rival to Lucentis in Great Britain. A launch is planned this year.
Stada and Xbrane have celebrated an endorsement from the EMA’s CHMP for their Ximluci ranibizumab biosimilar rival to Lucentis. The development follows a setback for a parallel filing in the US.